Discover the history of semaglutide—from early hormone research to FDA approval for type 2 diabetes and chronic weight management. Learn how licensed providers may explore GLP-1–based options with eligible patients.
Please note that this article is not meant to be medical advice; please consult with a licensed healthcare provider to determine best practices for your health.
Semaglutide’s development is rooted in GLP-1 research from the 1970s, when scientists like Jens Juul Holst began exploring the hormone’s potential role in supporting insulin secretion and regulating appetite. By the 1980s, early studies suggested that GLP-1 analogues might offer therapeutic benefits for managing type 2 diabetes.
Following the regulatory approval and clinical adoption of liraglutide in the late 1990s, Novo Nordisk began research aimed at developing a longer-acting GLP-1 receptor agonist:
Licensed healthcare providers on the Eden platform may discuss GLP-1–based treatment options that are appropriate for each individual's needs.
In the STEP clinical trials, participants with obesity or overweight receiving semaglutide alongside lifestyle interventions experienced average weight reductions of 14.9% to 17.4% over 68 weeks. These studies, published in peer-reviewed journals, were conducted in controlled environments with medical oversight. Individual outcomes may vary, and this data should not be interpreted as a guaranteed result outside of clinical settings. Licensed providers can evaluate whether GLP-1–based treatments are appropriate based on your individual health profile.
Some observational reports outside of controlled trials suggest that individuals prescribed semaglutide under licensed medical supervision may experience weight-related changes over several months. Reported weight changes have varied widely, and outcomes depend heavily on adherence, lifestyle factors, and individual response. These findings should not be used as a substitute for clinical trial data, and licensed providers can help patients understand what to expect based on their own health history.
Licensed healthcare providers on the Eden platform may help determine whether GLP-1–based treatments are appropriate for your individual needs.
Researchers are currently investigating whether GLP-1 receptor agonists may influence areas such as cardiovascular health, kidney function, liver metabolism, and sleep-related conditions. While some studies have explored these topics, these are not FDA-approved uses, and evidence remains limited or preliminary. Patients should speak with a licensed healthcare provider to understand what is supported by current research and what is still under evaluation.
In clinical studies, some participants reported appetite-related changes within the first 1–2 weeks, with weight-related changes sometimes observed between weeks 4 and 6. Results varied, and long-term success often involved lifestyle changes and regular medical supervision.
Eden is a platform through which patients may connect with licensed healthcare providers who can help assess whether GLP-1–based treatments may be appropriate for their goals.
In clinical trials, semaglutide was generally well-tolerated, though some participants experienced gastrointestinal symptoms such as nausea, constipation, or diarrhea. These effects were usually mild and tended to improve over time. More serious risks, such as pancreatitis or gallbladder issues, have also been reported and should be discussed with a licensed healthcare provider before starting any treatment.
Semaglutide’s development—rooted in decades of GLP-1 hormone research—represents a significant milestone in how clinicians approach certain chronic conditions like type 2 diabetes and obesity. It has shown promising results in controlled studies as an FDA-approved treatment under specific brand names.
Eden is a platform through which patients may connect with licensed healthcare providers who can evaluate whether GLP–1–based therapies may be appropriate based on their individual needs and goals.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Its formulation began in the early 2000s, following earlier work on GLP-1 analogues like liraglutide.
Ozempic® was approved in 2017 (type 2 diabetes), Rybelsus® in 2019 (oral form), and Wegovy® in 2021 (chronic weight management).
Some clinicians prescribed GLP-1–based medications for weight-related concerns prior to the FDA approval of semaglutide for chronic weight management under the brand name Wegovy® in 2021. In these cases, treatment decisions were made at the discretion of individual licensed healthcare providers based on each patient’s medical history and goals.
In clinical trials, some participants began noticing appetite changes within 1–2 weeks and reported weight-related changes over the following months. Individual results vary and depend on multiple factors including adherence, dosage, and lifestyle.
In controlled studies, some individuals treated with semaglutide and lifestyle support achieved up to 20% weight loss over 12–18 months. These results were observed in clinical settings and may not reflect outcomes in routine use.
